Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles P Sparrow

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Alimentary Pharmacology & Therapeutics|December 15, 2021
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in uteroEmma Flanagan, Ralley Prentice, Emily K Wright, et al.
Inflammatory Bowel Diseases|April 21, 2015
Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's DiseaseFenling Fan, Piyushkumar A Mundra, Lu Fang, et al.
Journal of Crohn'S & Colitis|May 17, 2019
Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort AnalysisRobert D Little, Isabel E Chu, Esmerij P van der Zanden, et al.
Gastroenterology & Hepatology|October 1, 2011
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupMiles P Sparrow, Peter M Irving, Leonard Baidoo, et al.
Journal of Crohn'S & Colitis|September 19, 2020
Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's DiseaseDanny Con, Nina Parthasarathy, Maria Bishara, et al.
Therapeutic Drug Monitoring|September 29, 2022
Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel DiseaseClarissa A Rentsch, Mark G Ward, Raphael P Luber, et al.
Journal of Gastroenterology and Hepatology|December 22, 2017
Predicting response after infliximab salvage in acute severe ulcerative colitisMatthew C Choy, Dean Seah, Alexandra Gorelik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2018
Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit AllGil Y Melmed, Gilaad G Kaplan, Miles P Sparrow, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 12, 2010
Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meetingDirk P van Asseldonk, Jeremy Sanderson, Nanne K H de Boer, et al.
Digestive Diseases and Sciences|January 27, 2025
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International StudySailish Honap, Bénédicte Caron, Jacob E Ollech, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Alimentary Pharmacology & Therapeutics|December 15, 2021
Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in uteroEmma Flanagan, Ralley Prentice, Emily K Wright, et al.
Inflammatory Bowel Diseases|April 21, 2015
Lipidomic Profiling in Inflammatory Bowel Disease: Comparison Between Ulcerative Colitis and Crohn's DiseaseFenling Fan, Piyushkumar A Mundra, Lu Fang, et al.
Journal of Crohn'S & Colitis|May 17, 2019
Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort AnalysisRobert D Little, Isabel E Chu, Esmerij P van der Zanden, et al.
Gastroenterology & Hepatology|October 1, 2011
Current Controversies in Crohn's Disease: A Roundtable Discussion of the BRIDGe GroupMiles P Sparrow, Peter M Irving, Leonard Baidoo, et al.
Journal of Crohn'S & Colitis|September 19, 2020
Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's DiseaseDanny Con, Nina Parthasarathy, Maria Bishara, et al.
Therapeutic Drug Monitoring|September 29, 2022
Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel DiseaseClarissa A Rentsch, Mark G Ward, Raphael P Luber, et al.
Journal of Gastroenterology and Hepatology|December 22, 2017
Predicting response after infliximab salvage in acute severe ulcerative colitisMatthew C Choy, Dean Seah, Alexandra Gorelik, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 6, 2018
Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit AllGil Y Melmed, Gilaad G Kaplan, Miles P Sparrow, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 12, 2010
Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meetingDirk P van Asseldonk, Jeremy Sanderson, Nanne K H de Boer, et al.
Digestive Diseases and Sciences|January 27, 2025
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International StudySailish Honap, Bénédicte Caron, Jacob E Ollech, et al.
Pageof 10